-
Cheaper versions of Wegovy and Zepbound touted on social media could be fleeting. Copies are legal now because the brand-name drugs are in short supply. But the drugmakers are boosting production.
-
New research shows that the number of 12- to 25-year-olds who used the GLP-1 medications climbed from about 8,700 a month in 2020 to 60,000 a month in 2023.
-
The makers of Ozempic and Mounjaro charge charge around $1,000 a month for the drugs, and insurers are reluctant to pick up the tab. Often, low-income patients have to resort to less effective treatments.
-
But some health experts worry about traditional diet companies and gyms getting in the medication business and believe the drugs will cater to society’s need for quick fixes.
-
The European Medicines Agency regulatory committee joins the FDA in saying there's no known tie between the semaglutide obesity drugs and suicide.
-
Health officials say a preliminary review finds no connection between suicidal thoughts and a new class of diabetes and obesity drugs, but they cannot definitively rule out “a small risk may exist."
-
Weight-loss medications tamp down hunger — often dramatically — causing some people to lose the pleasure of communing over food at a festive family meal.
-
Many welcome what they say is greater control over what they eat. “I don’t care about the bread as much. I still eat what I enjoy,” says one Tampa area woman who lost more than 200 pounds taking Mounjaro.
-
Wegovy is a high-dose version of the diabetes treatment Ozempic. The international trial showed the weekly injections prevented heart attacks, strokes and heart-related deaths.
-
Doctors and patients around the country say getting on the high-demand, injectable drugs requires persistence and a fair amount of luck.